Veeva Funding: How Much Did They Raise & Key Investors

How Much Did Veeva Raise?
Funding & Key Investors

Veeva has solidified its position as a cornerstone of the life sciences technology ecosystem, having secured a total capital infusion of $258M over its growth trajectory. The company's most recent strategic financing round, totaling $35M, underscores its continued dominance in providing mission-critical infrastructure for the pharmaceutical and biotechnology sectors. This capital injection serves as a testament to the firm's ability to scale complex, cloud-native solutions within highly regulated global markets.

By maintaining a consistent focus on industry-specific software, Veeva has successfully navigated multiple funding cycles, transitioning from early-stage venture backing to a mature enterprise-level entity. The latest investment round reflects investor confidence in the company's long-term roadmap and its capacity to drive digital transformation across the entire drug development and commercialization lifecycle.

What is Veeva?

Veeva

Software

Customer Engagement Platforms

Veeva operates as a premier provider of cloud-based software, data, and artificial intelligence solutions tailored specifically for the life sciences industry. Its integrated industry cloud platform empowers pharmaceutical, biotechnology, and medical device organizations to streamline research, optimize regulatory processes, and enhance engagement with healthcare professionals. By centralizing data and operational workflows, Veeva enables its clients to accelerate the delivery of life-saving therapies to patients worldwide. The company's market position is defined by its deep domain expertise and its ability to replace fragmented legacy systems with unified, scalable, and compliant cloud architectures.

How much funding has Veeva raised?

Veeva has raised a total of $258M across 4 funding rounds:

2007

Series A

$3M

2008

Series B

$4M

2013

Stock Offering

$216M

2014

Stock Offering

$35M

Series A (2007): $3M with participation from Undisclosed

Series B (2008): $4M led by Emergence Capital Partners

Stock Issuance/Offering (2013): $216M supported by Undisclosed

Stock Issuance/Offering (2014): $35M featuring Undisclosed

Key Investors in Veeva

Emergence Capital Partners

Emergence is a prominent venture capital firm specializing in early-stage enterprise software companies that are fundamentally changing how the world works.

Undisclosed Investors

What's next for Veeva?

With the support of its latest strategic capital, Veeva is well-positioned to expand its footprint in the rapidly evolving digital health landscape. The company is expected to prioritize the integration of advanced artificial intelligence and machine learning capabilities into its existing suite of products, further automating complex regulatory and clinical trial workflows. Furthermore, the firm is likely to pursue aggressive market penetration in emerging biotech hubs, leveraging its robust balance sheet to maintain its competitive edge against both incumbent software providers and agile, niche-focused startups. As the life sciences sector continues to prioritize data-driven decision-making, Veeva's strategic focus will remain on enhancing its platform's interoperability and expanding its global service delivery capabilities.

See full Veeva company page

See More Financial Insights